Overview
Esperion Therapeutics, based in Ann Arbor, Michigan, commercializes NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe), oral, once-daily non-statin therapies for lowering LDL cholesterol. It reported one business segment and 294 full-time employees at the end of 2025. Funds managed by ARCHIMED completed a take-private acquisition of Esperion on July 13, 2026, and its shares no longer trade on Nasdaq.
Hiring snapshot
Hiring by specialty
Top states
Open roles
Newest first, from Esperion Therapeutics’s careers page.
- Regional Sales ManagerSan Francisco Ca, San Francisco +19d ago
- National Director, Key AccountsRemote · Ann Arbor9d ago
- Territory Manager, SalesJackson Ms, Jackson9d ago
- Territory Manager, SalesSeattle Wa, Seattle9d ago
- Territory Manager, SalesAlbany S Ny, Albany S9d ago
- Territory Manager, SalesSan Francisco Ca, San Francisco9d ago
Divisions
Division information is pending company verification.Once Esperion Therapeutics claims its page, you will see each division, who it calls on and how it pays.
Claim your pageMore from Esperion Therapeutics
These sections fill in when Esperion Therapeutics claims and verifies its page.
Life at Esperion TherapeuticsPhotos, stories and culture. Not added yet.
BenefitsNot added yet.